Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

3127 - Prognostic significance of circulating regulatory T lymphocytes (Tregs) in patients with metastatic colorectal cancer (mCRC) under treatment with first line chemotherapy.

Date

29 Sep 2019

Session

Poster Display session 2

Topics

Tumour Site

Colon and Rectal Cancer

Presenters

Zafeiris Zafeiriou

Citation

Annals of Oncology (2019) 30 (suppl_5): v198-v252. 10.1093/annonc/mdz246

Authors

Z. Zafeiriou1, A. Koutoulaki2, F. Koinis3, D. Aggouraki2, N.K. Vardakis3, E.K. Vetsika2, K. Kotta4, D. Mavroudis1, V. Georgoulias1, A. Kotsakis2

Author affiliations

  • 1 Medical Oncology Department, School of Medicine, University of Crete, 712 01 - Heraklion/GR
  • 2 Laboratory Of Translational Oncology, School of Medicine, University of Crete, 712 01 - Heraklion/GR
  • 3 Medical Oncology, University Hospital of Heraklion (PAGNI), 712 01 - Heraklion/GR
  • 4 Department Of Biomedical Research, Institute of Applied Biosciences, – 57001 - Thessaloniki/GR

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3127

Background

In humans Tregs lack a unique phenotypic marker and Foxp3 expression in cluster of differentiation (CD) 4+CD25+ or CD4+CD25high T lymphocytes is commonly used for their characterization. In early colorectal cancer, the presence of Tregs in CRC tumour tissue has been associated with favourable prognosis. However, the prognostic role of circulating Tregs in CRC patients and especially in the metastatic setting is not yet clear.

Methods

We collected peripheral blood from 57 patients with mCRC before initiation of first line chemotherapy. Samples were analysed with multicolour flow cytometry using monoclonal antibodies against CD3, CD4, CD25, and FoxP3. The ratio of FoxP3 positive cells within the CD3+CD4+CD25high lymphocytic subpopulation (F/H ratio) was measured and quartile analysis according to this ratio was carried out. Overall survival was calculated from initiation of first line chemotherapy to death or last follow up. Median OS (mOS) was compared between the highest quartile and the rest using the Breslow (Generalized Wilcoxon) method. Ratios were compared between groups with the Mann Whitney U-test. Statistics were analyzed with SPSS and flow cytometry data with Kaluza 2.1.

Results

The median F/H ratio was 0,08 (Interquartile range 0,018-0,34) with a distribution skewed to the right (range 0 to 0.85). For each quartile mOS is shown in the table. The mOS for the highest quartile was 8 months (m) (95% Confidence Interval(CI) 0 - 20.6m) and 25m for the rest (95% CI 18.2m-31.8m)(p = 0.03). No difference was observed in F/H ratio in different groups according to KRAS/NRAS mutations’ status, prior adjuvant chemotherapy, performance status or sidedness of primary site.Table:

610P

QuartileF/H ratio (range)nmOS (m)mOS(m)p
1st0-0,018142425
2nd0,0181-0,081534
3rd0,0810-0,341524
4th0,3410-0,851380.03

Conclusions

The F/H ratio in patients with mCRC is spread over a wide range of values with the majority below 0.1. High values (>0.34) seem to have prognostic significance and be associated with worse outcome.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Medical School, University of Crete.

Funding

Hellenic Oncology Research Group, Medical School, University of Crete.

Disclosure

Z. Zafeiriou: Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Sanofi; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: Bristol. A. Koutoulaki: Full / Part-time employment: Genesis Pharma. V. Georgoulias: Travel / Accommodation / Expenses: Sanofi. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.